|Defined daily dose||3 gm|
|Chemical and physical data|
|Molar mass||332.353 g·mol−1|
|3D model (JSmol)|
|Melting point||184 to 194 °C (363 to 381 °F)|
|(what is this?)|
Common side effects include pain at the area of injection, rash, nausea, fever, and trouble sleeping. Severe allergic reactions may occasionally occur. It is generally safe to use during pregnancy. It may be used by those who are allergic to penicillin or cephalosporins. It is in the aminocyclitol class of drugs and works by stopping the making of protein by certain bacteria.
Spectinomycin was discovered in 1961. It is on the World Health Organization's List of Essential Medicines. The wholesale cost in the developing world is about US$5 per dose. It is not available in the United States for human use. It is made from the bacterium Streptomyces spectabilis.
This antibiotic is no longer available in the United States for human use, but is still available for veterinary use.
The defined daily dose is 3 grams. The dose is typically 2 to 4 grams injected into a muscle for gonorrhea. This is used as a one time dose for affected genitals, anus, or eyes. For gonorrhea that has spread within the body 2 gm twice per day for 7 days is recommended. For brucellosis it is given as 1 gram a day for two weeks well for plague it is used at a dose of 1 gram twice per day for 10 days in adults and 15 mg/kg every 12 hours in children.
Mechanism of action
Biosynthesis of spectinomycin begins similar to all aminoglycosides, with the formation of an inositol ring. The difference is the initial modification that forms the inositol ring of spectinomycin. The process begins with a glucose-6-phosphate (1a), which is reduced by NADH to form a ketone at C2 (2a). This ketone is then formed into a primary amine group through PLP and glutamine transamination (3a). This process is repeated again at C4 to form a second primary amine (4a). Once these two amines are present, the glucose ring is ready to be methylated through two S-adenosyl methionine molecules (5a). With this methylation, the glucose ring is finally ready to be converted into an inositol ring through inositol cyclase (6a). This can then be hydrolyzed to get rid of the phosphate group, making the inositol ring necessary for spectinomycin (7a).
While all this happens, an alternate pathway is occurring creating the sugar functional group from a similar starting product. In this pathway, glucose-1-phosphate is used as the starting product (1b). This is converted into a TDP glucose through TDP synthase (2b). TDP glucose then has the hydroxyl removed from C6 through a hydratase enzyme (3b), which is then reduced through NADH at C4 creating a new product (4b). With this ketone present, PLP and glutamine can come in to convert it to a primary amine (5b) which can then be removed through a deaminase (6b). This conversion to 6b is also accompanied by a double reduction at C4 and C3 through two more NADH molecules, giving the final product necessary to form the aminoglycoside. With this, products 7a and 6b can come together, removing the TDP functional group and combining with the sugar molecule to form the aminoglycoside spectinomycin.
It is in aminocyclitol class, closely related to the aminoglycosides. Spectinomycin is industrially produced by fermentation of the bacterium Streptomyces spectabilis. Spectinomycin is produced in nature by many organisms including cyanobacteria and various plant species. It is present in the genome or plastome of many plastids as the spc operon, which is usually two to 10 genes long. The difference in size may be due to the elimination of obsolete genes or the takeover of its function by nuclear genes. Spectinomycin is mainly produced by organisms as a defence mechanism against predators.
- "SPECTINOMYCIN injectable - Essential drugs". medicalguidelines.msf.org. Retrieved 17 August 2020. CS1 maint: discouraged parameter (link)
- "WHOCC - ATC/DDD Index". www.whocc.no. Retrieved 4 September 2020. CS1 maint: discouraged parameter (link)
- "Spectinomycin Hydrochloride". The American Society of Health-System Pharmacists. Archived from the original on 2015-09-24. Retrieved Sep 6, 2015. CS1 maint: discouraged parameter (link)
- Textbook of Drug Design and Discovery, Fourth Edition. CRC Press. 2009. p. 438. ISBN 9781439882405. Archived from the original on 2015-10-03. CS1 maint: discouraged parameter (link)
- World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- "Spectinomycin". International Drug Price Indicator Guide. Retrieved 7 September 2015. CS1 maint: discouraged parameter (link)
- "STREPTOMYCIN injectable - Essential drugs". medicalguidelines.msf.org. Retrieved 4 September 2020. CS1 maint: discouraged parameter (link)
- Kehrenberg C, Schwarz S (June 2007). "Mutations in 16S rRNA and ribosomal protein S5 associated with high-level spectinomycin resistance in Pasteurella multocida". Antimicrob. Agents Chemother. 51 (6): 2244–6. doi:10.1128/AAC.00229-07. PMC 1891365. PMID 17371823.
- Dewick, Paul M. (4 Feb 2009). Medicinal Natural Products: A Biosynthetic Approach, 3rd Edition. Wiley Online Library: Wiley. pp. 485–508. doi:10.1002/9780470742761. ISBN 9780470741689.
- "From the Centers for Disease Control and Prevention. Update on spectinomycin availability in the United States". JAMA. 286 (11): 1308–9. September 2001. doi:10.1001/jama.286.11.1308. PMID 11575327.